Tirzepatide TIRZ

An FDA-approved medication (Mounjaro for diabetes, Zepbound for obesity), currently the most effective approved weight-loss drug on the market. Large human trials show substantial weight loss and strong blood sugar control, usually beating older single-mechanism drugs, with nausea and other stomach issues being the most common complaints.

Also known as Mounjaro, Zepbound, Mounjaro (TN), Zepbound (TN), Tirzepatide free base?, Tirzepatide (JAN/USAN), D11360

Effects Lose fat

Routes Subcutaneous

Legal status Prescription drug

WADA Not listed

Molecular Structure of C₂₂₅H₃₄₈N₄₈O₆₈

Drag to rotate · scroll to zoom

PubChem has no 3D conformer for this molecule, so this is the flat structure.

Chemistry

Formula: C225H348N48O68
Molar mass: 4813
CAS: 2023788-19-2
PubChem CID: 166567236
IUPAC name: 20-[[(1S)-4-[2-[2-[2-[2-[2-[2-[[(5S)-5-[[(2S)-5-amino-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-2-methylpropanoyl]amino]-4-carboxybutanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxypropanoyl]amino]-3-methylpentanoyl]amino]-2-methylpropanoyl]amino]-4-methylpentanoyl]amino]-3-carboxypropanoyl]amino]hexanoyl]amino]-3-methylpentanoyl]amino]propanoyl]amino]-5-oxopentanoyl]amino]-6-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[2-[[2-[(2S)-2-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[(2S)-2-[(2S)-2-[(2S)-2-[[(2S)-1-amino-3-hydroxy-1-oxopropan-2-yl]carbamoyl]pyrrolidine-1-carbonyl]pyrrolidine-1-carbonyl]pyrrolidin-1-yl]-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-2-oxoethyl]amino]-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxopropan-2-yl]amino]-6-oxohexyl]amino]-2-oxoethoxy]ethoxy]ethylamino]-2-oxoethoxy]ethoxy]ethylamino]-1-carboxy-4-oxobutyl]amino]-20-oxoicosanoic acid
InChIKey: BTSOGEDATSQOAF-MCNPHUAVSA-N

Reported dosing

Approved label

What has been reported in the literature and by users. This is a record of what is done, not a recommendation.

Typical dose 5-10 mg once weekly (may titrate to 15 mg)

Reported range 2.5-15 mg once weekly, titrated

Route Subcutaneous injection

Frequency Once weekly

Duration Chronic/ongoing (as prescribed)

FDA-approved dual GIP/GLP-1 receptor agonist (Mounjaro for diabetes, Zepbound for obesity). Compounded 'generic' versions sold by some telehealth/gray-market sources are not FDA-approved as standardized products.

Where this comes from FDA prescribing information

These figures are recorded for reference and are not a recommendation. Dosing is a decision for you and a clinician.